May Monthly Winner of Merseyside Innovation Awards Announced


A Liverpool based company which has developed a groundbreaking cancer test has been named the Merseyside Innovation Awards winner for May.
MIA Logo 2014
ProKyma, based at Liverpool Science Park, is hoping its discovery can improve cancer survival rates.

The company is working with the University of Liverpool to develop a personalised blood test to measure the level of cancer cells in a patient's blood.

The project is still in the research phase but if successful it would enable doctors to determine in real time whether a course of treatment is working and whether a cancer has been completely eradicated from the body. It may also allow the development of more mild cancer treatments.

Once the research and testing phase is complete, ProKyma plans to offer the test to pharmaceutical companies to use as part of their screening process for cancer drug candidates and build a manufacturing base in Merseyside.

ProKyma has been backed by the National Institute for Health Research with £500,000 in funding and also secured further investment from the North West Fund for Biochemical in 2013 to move to Liverpool Science Park.

The business is led by chief executive Damian Bond and chairman Chris Stanley.

Bond said: "A lot of the research which is trying to detect cancer cells in the blood at the moment is working to try to find a way to make cancer cells stick to probes in order to identify them in blood.

"But the cells are very hard to detect and are often masked by millions of white blood cells, so it is really a case of finding a needle in a haystack. We have approached the problem from a different angle.

"By using antibodies to make the white blood cells stick to the probe, we can effectively remove the haystack by removing the plentiful white blood cells. By doing this, we know that the cells left behind are cancer cells.

"Around 50 per cent of people with cancer today will die within five years. But most of the time the primary tumour is not what kills a patient, it is the secondary tumour that implants elsewhere in the body as a result of these cancerous cells in the blood.

"Our aim is to use our technology to allow doctors to identify whether a cancer has returned before any visible indicators or symptoms present themselves in order to prevent deadly secondary cancers implanting."

The 2014 Merseyside Innovation Awards are now in their 19th year. A winner is selected each month and at the end of the entry period the applicants are whittled down to three finalists who will be invited to give a presentation to the judges at the final talking place at the Crowne Plaza, Liverpool in July.

The winner will receive a prize of £10,000 in cash while the runners-up can win specialist business support worth up to £2,000.

MC Vanguard are once again proud to support the ceremony.

The other sponsors are BBC Radio Merseyside, Brabners, Kenyon Fraser, Unilever, Liverpool Chamber of Commerce, Liverpool LEP, NatWest, University of Liverpool Management School, Insider, Village Software, Butters Innovation, WP Thompson, C-Tech Innovation, Trustech Smart Healthcare Ventures and the North West Fund.

This story first appeared in Insider North West on Friday 30 May and can be found here.

Post a comment

Registered to carry on audit work in the UK and Ireland by the Institute of Chartered Accountants in England and Wales and authorised and regulated by the Financial Conduct Authority for investment business